UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

British journal of cancer, 2020-12, Vol.123 (12), p.1730-1736

2020

Volltextzugriff (PDF)

Analysis of Unstirred Water Layer in In Vitro Permeability Experiments

Journal of pharmaceutical sciences, 2009-12, Vol.98 (12), p.4469-4479

2009

Volltextzugriff (PDF)

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

European journal of drug metabolism and pharmacokinetics, 2019-12, Vol.44 (6), p.747-759

2019

Volltextzugriff (PDF)

TRPA1: A Transducer and Amplifier of Pain and Inflammation

Basic & clinical pharmacology & toxicology, 2014-01, Vol.114 (1), p.50-55

2014

Volltextzugriff (PDF)

Transient Receptor Potential Ankyrin 1 Ion Channel Contributes to Guarding Pain and Mechanical Hypersensitivity in a Rat Model of Postoperative Pain

Anesthesiology (Philadelphia), 2012-07, Vol.117 (1), p.137-148

2012

Volltextzugriff (PDF)

Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories

European journal of pharmaceutical sciences, 2008-12, Vol.35 (5), p.383-396

2008

Volltextzugriff (PDF)

Use of comprehensive screening methods to detect selective human CAR activators

Biochemical pharmacology, 2011-12, Vol.82 (12), p.1994-2007

2011

Volltextzugriff (PDF)

The Asymmetry of the Unstirred Water Layer in Permeability Experiments

Pharmaceutical research, 2008-07, Vol.25 (7), p.1714-1722

2008

Volltextzugriff (PDF)

Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates

The Journal of pharmacology and experimental therapeutics, 2009-03, Vol.328 (3), p.882

2009

Volltextzugriff (PDF)

Effects of Experimental Setup on the Apparent Concentration Dependency of Active Efflux Transport in in Vitro Cell Permeation Experiments

Molecular pharmaceutics, 2010-04, Vol.7 (2), p.605-617

2010

Volltextzugriff (PDF)

Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates

Drug metabolism and disposition, 2007-09, Vol.35 (9), p.1574

2007

Volltextzugriff (PDF)

Predicting the effect of prandial stage and particle size on absorption of ODM-204

European journal of pharmaceutics and biopharmaceutics, 2020-11, Vol.156, p.75-83

2020

Volltextzugriff (PDF)

Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.297-297

2019

Volltextzugriff (PDF)

How to stop disproportionation of a hydrochloride salt of a very weakly basic compound in a non-clinical suspension formulation

International journal of pharmaceutics, 2021-09, Vol.606, p.120875-120875, Article 120875

2021

Volltextzugriff (PDF)

Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats

Xenobiotica, 2020-08, Vol.50 (8), p.967-979

2020

Volltextzugriff (PDF)

5-HT6 receptor antagonists. Design, synthesis, and structure–activity relationship of substituted 2-(1-methyl-4-piperazinyl)pyridines

Bioorganic & medicinal chemistry letters, 2023-11, Vol.96, p.129497-129497, Article 129497

2023

Volltextzugriff (PDF)

Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020)

Drug metabolism letters, 2021, Vol.14 (1), p.9

2021

Volltextzugriff (PDF)

Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans

Drug metabolism and disposition, 2021-06, Vol.49 (6), p.420-433

2021

Volltextzugriff (PDF)

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.28-38

2019

Volltextzugriff (PDF)

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1753-1753

2020

Volltextzugriff (PDF)

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

European journal of pharmaceutical sciences, 2017-01, Vol.96, p.626-642

2017

Volltextzugriff (PDF)

5-HT 6 receptor antagonists. Design, synthesis, and structure-activity relationship of substituted 2-(1-methyl-4-piperazinyl)pyridines

Bioorganic & medicinal chemistry letters, 2023-11, Vol.96, p.129497

2023

Volltextzugriff (PDF)

1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists

Bioorganic & medicinal chemistry letters, 2016-06, Vol.26 (11), p.2610-2615

2016

Volltextzugriff (PDF)

Modelling of Drug Disposition Kinetics in In Vitro Intestinal Absorption Cell Models

Basic & clinical pharmacology & toxicology, 2010-03, Vol.106 (3), p.180-188

2010

Volltextzugriff (PDF)

Abstract 4133: ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong activity on primary and metastatic tumor growth in FGFR-dependent and angiogenic cancer models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4133-4133

2015

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Pharmacology & Pharmacy
(23)
Humans
(20)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Pharmacology. Drug Treatments
(13)
Animals
(8)
Caco-2 Cells
(8)
Permeability
(8)
Chemistry
(7)
General Pharmacology
(7)
Pharmaceutical Technology. Pharmaceutical Industry
(7)
Physical Sciences
(7)
Male
(5)
Pharmacokinetics
(5)
Absorption
(4)
Biological Transport
(4)
Chemistry, Medicinal
(4)
Dose-Response Relationship, Drug
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Analysis of Unstirred Water Layer in In Vitro Permeability Experiments

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

TRPA1: A Transducer and Amplifier of Pain and Inflammation

Transient Receptor Potential Ankyrin 1 Ion Channel Contributes to Guarding Pain and Mechanical Hypersensitivity in a Rat Model of Postoperative Pain

Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories

Use of comprehensive screening methods to detect selective human CAR activators

The Asymmetry of the Unstirred Water Layer in Permeability Experiments

Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates

Effects of Experimental Setup on the Apparent Concentration Dependency of Active Efflux Transport in in Vitro Cell Permeation Experiments

Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates

Predicting the effect of prandial stage and particle size on absorption of ODM-204

Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies

How to stop disproportionation of a hydrochloride salt of a very weakly basic compound in a non-clinical suspension formulation

Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats

5-HT6 receptor antagonists. Design, synthesis, and structure–activity relationship of substituted 2-(1-methyl-4-piperazinyl)pyridines

Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020)

Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

5-HT 6 receptor antagonists. Design, synthesis, and structure-activity relationship of substituted 2-(1-methyl-4-piperazinyl)pyridines

1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists

Modelling of Drug Disposition Kinetics in In Vitro Intestinal Absorption Cell Models

Abstract 4133: ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong activity on primary and metastatic tumor growth in FGFR-dependent and angiogenic cancer models

Suchergebnisse filtern